Aevi Genomic Medicine (GNMX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2015 | 09-2015 | 06-2015 | 03-2015 | 12-2014 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -37,992 | -31,529 | -15,008 | -8,922 | -18,433 |
| Depreciation Amortization | 240 | 181 | 124 | 43 | 225 |
| Accounts receivable | N/A | -780 | -1,789 | -1,278 | -113 |
| Accounts payable and accrued liabilities | 246 | 355 | -334 | -589 | 14 |
| Other Working Capital | -102 | 5,547 | -2,845 | -3,436 | 470 |
| Other Operating Activity | 13,261 | 9,348 | 8,216 | 6,039 | 5,642 |
| Operating Cash Flow | $-24,347 | $-16,878 | $-11,636 | $-8,143 | $-12,195 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -187 | -113 | -100 | -18 | -363 |
| Investing Cash Flow | $-187 | $-113 | $-100 | $-18 | $-363 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 44,310 | 1,428 | 460 | 32 | 23,456 |
| Financing Cash Flow | $44,310 | $1,428 | $460 | $32 | $23,456 |
| Beginning Cash Position | 33,288 | 33,288 | 33,288 | 33,288 | 22,390 |
| End Cash Position | 53,064 | 17,725 | 22,012 | 25,159 | 33,288 |
| Net Cash Flow | $19,776 | $-15,563 | $-11,276 | $-8,129 | $10,898 |
| Free Cash Flow | |||||
| Operating Cash Flow | -24,347 | -16,878 | -11,636 | -8,143 | -12,195 |
| Capital Expenditure | -187 | -113 | -100 | -18 | -364 |
| Free Cash Flow | -24,534 | -16,991 | -11,736 | -8,161 | -12,559 |